IHS FormWeb
Approved Formulary
Search by name
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Restricted Medications
Renal Adjustment Policy
Therapeutic Interchange Policy
Hazard.Drug Handling(USP 800)
Hazardous Waste
Chemotherapy
IV to PO Conversion Policy
Black Box Warnings
Look-Alike/Sound-Alike
REMS
Staff Telephone Numbers
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
IHS FormWeb
Approved Formulary
Search by name
Additional search options
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
High Alert
Restricted Medications
Renal Adjustment Policy
Therapeutic Interchange Policy
Hazard.Drug Handling(USP 800)
Hazardous Waste
Chemotherapy
IV to PO Conversion Policy
Black Box Warnings
Look-Alike/Sound-Alike
REMS
Staff Telephone Numbers
Webpage Links
Search results for:
lacosamide
lacosamide
Brand names:
Vimpat
Form
Strength
SOLUTION, INTRAVENOUS
200 mg/20 mL
TABLET, ORAL
50 mg; 100 mg
Display
Anticonvulsants, Miscellaneous
Class:
281292
Medication comments:
IV lacosamide should be limited to 5 days of consecutive treatment. Evaluate patients around the 5 day mark and discuss changing to oral therapy with the physician as appropriate.
Last updated:
Jul. 22, 2017
UpToDate
FDA DailyMed Package Insert
MedLinePlus (Patient Information)
MSDS Online